Phoenix biotech startup emerges with $60M in backing to develop cancer therapies

Breakthru Medicine is using a new infusion of $60 million in capital to advance its solid tumor cancer therapies from the investigational new drug development stage to clinical trials, which are targeted to begin in 2027.